U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CVM GFI #283 Priority Zoonotic Animal Drug Designation and Review Process
  1. Search for FDA Guidance Documents


CVM GFI #283 Priority Zoonotic Animal Drug Designation and Review Process December 2023


Not for implementation. Contains non-binding recommendations.

Docket Number:
Issued by:
Guidance Issuing Office
Center for Veterinary Medicine

The Coronavirus Aid, Relief, and Economic Security (CARES) Act, signed into law in March 2020, added section 512A Priority zoonotic animal drugs to the FD&C Act, which provides for the designation of a new animal drug as a PZAD.  This legislation is intended to expedite the development and review of certain new animal drugs that have the potential to prevent or treat a zoonotic disease in animals, including a vector-borne disease, that has the potential to cause serious adverse health consequences for, or serious or life-threatening diseases in, humans.

This guidance outlines the eligibility criteria a new animal drug should meet to obtain PZAD designation and describes the process sponsors may use to request such designation.  In addition, this guidance identifies enhancements to expedite the PZAD review process.

Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2023-D-3740.


Contact Point
Dr. Michelle Hyre
Center for Veterinary Medicine
Food and Drug Administration
7500 Standish Place, HFV-133
Rockville, MD 20855
Back to Top